Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 25;6(2):373-375.
doi: 10.1182/bloodadvances.2021006006.

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Paola Guglielmelli  1 , Arianna Ghirardi  2 , Alessandra Carobbio  2 , Arianna Masciulli  2 , Chiara Maccari  1 , Barbara Mora  3 , Elisa Rumi  4 , Ana Triguero  5 , Maria Chiara Finazzi  6 , Helna Pettersson  7 , Chiara Paoli  8 , Francesco Mannelli  8 , Daniele Vanni  4 , Alessandro Rambaldi  6 , Francesco Passamonti  3 , Alberto Alvarez-Larràn  5 , Bjorn Andreasson  7 , Alessandro M Vannucchi  1 , Tiziano Barbui  2
Affiliations

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Paola Guglielmelli et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Ten-year OS after start of HU and RUXO in PS-matched groups. Kaplan-Meier survival curves according to time after diagnosis to first administration of RUXO (red solid line) or HU (blue dotted line). The number of patients at risk is plotted every year. P-values were calculated by log-rank test.
See this image and copyright information in PMC

Comment in

References

    1. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145-162. - PubMed
    1. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. ; COMFORT Investigators . A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9): 1139-1145. - PMC - PubMed
    1. Verstovsek S, Mesa RA, Gotlib J, et al. ; COMFORT-I investigators . Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55. - PMC - PubMed
    1. Barbui T, Masciulli A, Scarano M, et al. . Towards a better understanding of epidemiology, survival and treatment in myeloproliferative neoplasms: results of the European LeukemiaNet Registry (ERNEST study) [abstract]. Blood. 2014;124(21). Abstract 1849. - PubMed
    1. Cervantes F, Dupriez B, Pereira A, et al. . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901. - PubMed